Predicted impact of lipid lowering therapy on cardiovascular and economic outcomes of Swedish atherosclerotic cardiovascular disease guideline

被引：0
|
作者：
Gunilla Journath
Kristina Hambraeus
Emil Hagström
Billie Pettersson
Mickael Löthgren
机构：
[1] Karolinska University Hospital,Cardiology unit, Department of Medicine, Karolinska Institutet
[2] Falun Hospital,Department of Cardiology
[3] Uppsala University,Uppsala Clinical Research Center, and Department of Medical Sciences
[4] Amgen Inc,undefined
[5] Thousand Oaks,undefined
[6] Amgen (Europe) GmbH,undefined
来源：
BMC Cardiovascular Disorders | / 17卷
关键词：
Cardiovascular disease; Costs; Guidelines; Lipids; Myocardial infarction;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Lipid-lowering therapy and primary prevention of cardiovascular disease
    Mascitelli, Luca
    Pezzetta, Francesca
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2007, 18 (05) : 446 - 446
  • [22] Current Guideline Risk Stratification and Cardiovascular Outcomes in Chinese Patients Suffered From Atherosclerotic Cardiovascular Disease
    Li, Sha
    Liu, Hui-Hui
    Guo, Yuan-Lin
    Zhu, Cheng-Gang
    Wu, Na-Qiong
    Xu, Rui-Xia
    Dong, Qian
    Qian, Jie
    Dou, Ke-Fei
    Li, Jian-Jun
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [23] Cholesterol-lowering statin therapy to prevent atherosclerotic cardiovascular disease-Is the new guideline based on best evidence?
    Canoy, Dexter
    PREVENTIVE MEDICINE, 2014, 69 : 317 - 318
  • [24] Vascular Quality of Care Assessment: Clinicians' Adherence to Lipid-Lowering Therapy for Patients with Atherosclerotic Cardiovascular Disease
    Chan, Joyce
    Rajalingam, Tharshan
    Fossella, Jonathon
    Zhou, Hui
    Eisenberg, Naomi
    Roche-Nagle, Graham
    ANNALS OF VASCULAR SURGERY, 2020, 69 : 197 - 205
  • [25] Lipoprotein(a) and Atherosclerotic Cardiovascular Disease, the Impact of Available Lipid-Lowering Medications on Lipoprotein(a): An Update on New Therapies
    Tsushima, Takahiro
    Tsushima, Yumiko
    Sullivan, Claire
    Hatipoglu, Betul
    ENDOCRINE PRACTICE, 2023, 29 (06) : 491 - 497
  • [26] ADHERENCE TO LIPID-LOWERING THERAPY IS ASSOCIATED WITH LESS HOSPITALIZATION AND DEATH IN US VETERANS WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASE
    Marciniak, Roman
    Ward, Rachel
    Welman, Helen
    Young, Melissa
    Yel, Nedim
    McEligott, Sean
    Niu, Xiaoli
    Gagnon, David
    Djousse, Luc
    Gaziano, J. Michael
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2025, 85 (12) : 612 - 612
  • [27] LIPID PROFILE AND LIPID-LOWERING THERAPY AMONG ACUTE MYOCARDIAL INFARCTION PATIENTS WITHOUT PREVIOUS ATHEROSCLEROTIC CARDIOVASCULAR DISEASE
    Essa, Mohammed
    Lu, Yuan
    Huang, Haocheng
    Desai, Nihar R.
    Spatz, Erica Sarah
    Krumholz, Harlan M.
    Dajani, Abdel R.
    Mankbadi, Michael
    Kay, Bradley
    Faridi, Kamil
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 83 (13) : 1987 - 1987
  • [28] Association of APOE polymorphisms with lipid-lowering efficacy of statins in atherosclerotic cardiovascular disease
    Wang, Yuexi
    Du, Xiaohong
    Zhao, Ruifen
    Niu, Juan
    Wang, Haixu
    Li, Jing
    ANNALS ACADEMY OF MEDICINE SINGAPORE, 2021, 50 (06) : 474 - 480
  • [29] Time to benefit of intensive lipid lowering therapy in individuals with cardiovascular disease
    Li, Linjie
    Huang, Chuanyi
    Liu, Wennan
    Li, Jingge
    Geru, A.
    Chen, Xiaozhi
    Jiang, Shichen
    Fang, Yiwen
    Foo, Roger Sik-Yin
    Chan, Mark Yan-Yee
    Yu, Ying
    Li, Yongle
    Yang, Qing
    Zhou, Xin
    JOURNAL OF CLINICAL LIPIDOLOGY, 2025, 19 (01) : 51 - 59
  • [30] Lipid lowering therapy in cardiovascular disease: From myth to molecular reality
    Mourikis, Philipp
    Zako, Saif
    Dannenberg, Lisa
    Nia, Amir M.
    Heinen, Yvonne
    Busch, Lucas
    Richter, Hannah
    Hohlfeld, Thomas
    Zeus, Tobias
    Kelm, Malte
    Polzin, Amin
    PHARMACOLOGY & THERAPEUTICS, 2020, 213
12345